logo-loader
viewVolitionRx

VolitionRx to present at 2nd Annual Disruptive Growth & Healthcare Conference

VolitionRx Limited will present at Source Capital Group's 2nd Annual Disruptive Growth & Healthcare Conference being held on February 15-16 in New York

conference_speaker,_sized.png
VolitionRx to speak at New York conference

VolitionRx Limited (NYSEMKT:VNRX) will present at Source Capital Group's 2nd Annual Disruptive Growth & Healthcare Conference being held on February 15-16 in New York.

Scott Powell, Executive Vice President of Volition, will provide an update on Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced product launch of its Nu.QTM Colorectal Cancer Screening Triage Test.

Quick facts: VolitionRx

Price: 4.48 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $184.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay. He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma...

1 week, 5 days ago

2 min read